Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

OPTI-CLEAN · Effective and reliable optical system for cleaning validation in pharmaceuticals manufacture

FP7Status: CLOSED1 November 201131 October 2013EU funding €1,149,720

Cleaning validation in the pharmaceutical industry is the verification that the cleaning procedure used to remove contaminants from equipment surfaces is successfully reproducible. In pharmaceutical manufacture, plants or individual pieces of equipment may be dedicated to individual products or indeed used in multi-product manufacture. Cleaning should be carried out as soon as practical after the end of processing and should leave the plant in a suitable condition for next use. The impact of inadequate cleaning procedures is that any of a number of contaminants may be present in the next batch manufactured on the equipment. Current cleaning validation techniques are largely based on laborious, time consuming and expensive swab sampling techniques, whereby swabs of the cleaned surface are taken and then tested using HPLC techniques in the laboratory. Equipment can be down for days, which poses enormous economic burden in the pharmaceutical industry.The proposed project will build on the promising results of preliminary research using NIR Chemical Imaging technology to detect on surfaces low concentrations of APIs and detergents used in pharmaceutical manufacture. The results have shown the feasibility of such technology to be used to provide accurate information in real-time, thereby opening up the possibility for the development of a custom-made version of the technology that could be trialled and validated for its use in the pharmaceutical industry as a cleaning validation tool. A portable imaging device will be designed and built and tested on a commonly used APIs and detergents in real pharmaceutical environments in order to validate its effectiveness and reliability. The impact of the uptake of the technology will enable rapid turn-around times, increased through-put and profitability in EU pharmaceutical plants, as well as increased safety standards, which are paramount to safeguarding the health and safety of EU citizens.

Consortium · 8 organisations

coordinator

INNOPHARMA LABS LIMITED

IE · €678,282

participant

RITA INVEST OY

FI · €181,302

participant

MERRION PHARMACEUTICALS IRELAND LTD

IE · €6,480

participant

INSTITIUID TEICNEOLAIOCHTA BHAILE ATHA CLIATH

IE · €12,800

participant

KUAVA OY

FI · €138,760

participant

TEKNOLOGIAN TUTKIMUSKESKUS VTT

FI · €6,045

participant

IRIS TECHNOLOGY SOLUTIONS, SOCIEDAD LIMITADA

ES · €10,282

participant

MANUFACTURAS SERVIPLAST SA

ES · €115,769

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.